In our previous studies, two antidiabetic drugs, specifically metformin and pioglitazone (a PPARγ agonist), that improve insulin resistance and cross the blood-brain-barrier [10,11], reduced the risk of dementia in a dose-response pattern in patients with type 2 diabetes mellitus [12,13]. Here, PPARG is linked to Insulin resistance.